Archives of Osteoporosis

, 8:127

Clinical and economic characteristics of hip fracture patients with and without muscle atrophy/weakness in the United States

Original Article
  • 232 Downloads

Abstract

Summary

This retrospective analysis of hip fracture patients with and without muscle atrophy/weakness (MAW) revealed that those with MAW had significantly higher healthcare utilization and costs compared with hip fracture patients without MAW.

Purpose

Examine the demographics, clinical characteristics, and healthcare resource utilization and costs of hip fracture patients with and without MAW.

Methods

Using a large US claims database, individuals who were newly hospitalized for hip fracture between 1 Jan 2006 and 30 September 2009 were identified. Patients aged 50–64 years with commercial insurance (Commercial) or 65+ years with Medicare supplemental insurance (Medicare) were included. The first hospitalization for hip fracture was defined as the index stay. Patients were categorized into three cohorts: patients with medical claims associated with MAW over the 12 months before the index stay (pre-MAW), patients whose first MAW claim occurred during or over the 12 months after the index stay (post-MAW), and patients without any MAW claim (no-MAW). Multivariate regressions were performed to assess the association between MAW and healthcare costs over the 12-month post-index period, as well as the probability of re-hospitalization.

Results

There were 26,122 Medicare (pre-MAW, 839; post-MAW, 2,761; no-MAW, 22,522) and 5,100 Commercial (pre-MAW, 132; post-MAW, 394; no-MAW, 4,574) hip fracture patients included in this study. Controlling for cross-cohort differences, both the pre-MAW and post-MAW cohorts had significantly higher total healthcare costs (Medicare, $7,308 and $18,753 higher; Commercial, $18,679 and $25,495 higher) than the no-MAW cohort (all p < 0.05) over the 12-month post-index period. The post-MAW cohort in both populations was also more likely to have any all-cause or fracture-related re-hospitalization during the 12-month post-index period.

Conclusions

Among US patients with hip fractures, those with MAW had higher healthcare utilization and costs than patients without MAW.

Keywords

Hip fracture Muscle atrophy/weakness Healthcare utilization Costs 

References

  1. 1.
    Bischoff-Ferrari HA (2011) The role of falls in fracture prediction. Curr Osteoporos Rep 9(3):116–121PubMedCrossRefGoogle Scholar
  2. 2.
    Bass E, French DD, Bradham DD, Rubenstein LZ (2007) Risk-adjusted mortality rates of elderly veterans with hip fractures. Ann Epidemiol 17(7):514–519PubMedCrossRefGoogle Scholar
  3. 3.
    Braithwaite RS, Col NF, Wong JB (2003) Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc 51(3):364–370PubMedCrossRefGoogle Scholar
  4. 4.
    Hopley C, Stengel D, Ekkernkamp A, Wich M (2010) Primary total hip arthroplasty versus hemiarthroplasty for displaced intracapsular hip fractures in older patients: systematic review. BMJ 340:c2332–c2332, jun11 1PubMedCrossRefGoogle Scholar
  5. 5.
    Cooper C, Campion G, Melton LJ 3rd (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2(6):285–289PubMedCrossRefGoogle Scholar
  6. 6.
    National Center for Health Statistics (US) (2010) “Health, United States, 2009; with special feature on medical technology,” National Center for Health Statistics (US), Hyattsville (MD) JanGoogle Scholar
  7. 7.
    American Academy of Orthopaedic Surgeons, “Hip fractures,” aaos.org, [Online]. Available: http://orthoinfo.aaos.org/topic.cfm?topic=A00392Apr 2009
  8. 8.
    Butler M, Forte M, Kane R et al (2009) “Treatment of common hip fractures. Rockville (MD): Agency for Healthcare Research and Quality (US)”, Evidence reports/technology assessments vol. no. 184, AugGoogle Scholar
  9. 9.
    Creditor MC (1993) Hazards of hospitalization of the elderly. Ann Intern Med 118(3):219–223PubMedCrossRefGoogle Scholar
  10. 10.
    Visser M, Harris TB, Fox KM, Hawkes W, Hebel JR, Yahiro JY, Michael R, Zimmerman SI, Magaziner J (2000) Change in muscle mass and muscle strength after a hip fracture: relationship to mobility recovery. J Gerontol A Biol Sci Med Sci 55(8):M434–M440PubMedCrossRefGoogle Scholar
  11. 11.
    Bhave A, Marker DR, Seyler TM, Ulrich SD, Plate JF, Mont MA (2007) Functional problems and treatment solutions after total hip arthroplasty. J Arthroplasty 22(6 Suppl 2):116–124PubMedCrossRefGoogle Scholar
  12. 12.
    Rasch A, Byström AH, Dalén N, Martinez-Carranza N, Berg HE (2009) Persisting muscle atrophy two years after replacement of the hip. J Bone Joint Surg Br 91(5):583–588PubMedCrossRefGoogle Scholar
  13. 13.
    Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP (2008) The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 61(12):1234–1240PubMedCrossRefGoogle Scholar
  14. 14.
    The Bureau of Labor Statistics, “Databases, tables & calculators by subject: inflation and prices”Google Scholar
  15. 15.
    Greene W H (2002) Econometric analysis, 5th ed. Upper Saddle River, NJ, Prentice HallGoogle Scholar
  16. 16.
    Afifi AA, Kotlerman JB, Ettner SL, Cowan M (2007) Methods for improving regression analysis for skewed continuous or counted responses. Annu Rev Public Health 28(1):95–111PubMedCrossRefGoogle Scholar
  17. 17.
    Efron B, Tibshirani R (1993) An introduction to the bootstrap. Boca Raton, FL, CRC PressGoogle Scholar
  18. 18.
    Landi F, Liperoti R, Fusco D, Mastropaolo S, Quattrociocchi D, Proia A, Russo A, Bernabei R, Onder G (2012) Prevalence and risk factors of sarcopenia among nursing home older residents. J Gerontol A Biol Sci Med Sci 67(1):48–55PubMedCrossRefGoogle Scholar
  19. 19.
    Wehren LE, Hawkes WG, Hebel JR, Orwig DL, Magaziner J (2005) Bone mineral density, soft tissue body composition, strength, and functioning after hip fracture. J Gerontol A Biol Sci Med Sci 60(1):80–84PubMedCrossRefGoogle Scholar
  20. 20.
    Fox KM, Magaziner J, Hawkes WG, Yu-Yahiro J, Hebel JR, Zimmerman SI, Holder L, Michael R (2000) Loss of bone density and lean body mass after hip fracture. Osteoporos Int 11(1):31–35PubMedCrossRefGoogle Scholar
  21. 21.
    Centers for Disease Control and Prevention (2010) “National Hospital Discharge Survey: 2006 annual summary,” Vital and Health Statistics Number 168, DecGoogle Scholar
  22. 22.
    Pasoto S G, Yoshihara L A K, Maeda L C, Bernik M M S, Lotufo P A, Bonfa E, Pereira R M R (2011) “Osteoporotic hip fractures in non-elderly patients: relevance of associated co-morbidities,” Rheumatol. Int: SepGoogle Scholar
  23. 23.
    Heuberger RA (2011) The frailty syndrome: a comprehensive review. J Nutr Gerontol Geriatr 30(4):315–368PubMedCrossRefGoogle Scholar
  24. 24.
    Topinková E (2008) Aging, disability and frailty. Ann Nutr Metab 52 Suppl 1:6–11PubMedGoogle Scholar
  25. 25.
    Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB (2009) Incidence and mortality of hip fractures in the United States. JAMA 302(14):1573–1579PubMedCrossRefGoogle Scholar
  26. 26.
    Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C (2009) Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int 20(10):1633–1650PubMedCrossRefGoogle Scholar
  27. 27.
    Bhattacharya A, Leigh JP (2011) Musculoskeletal disorder cots and medical claim filing in the US retail trade sector. Ind Heal 49:517–522CrossRefGoogle Scholar
  28. 28.
    Wijnhoven HAH, de Vet HCW, Picavet HSJ (2006) Prevalence of musculoskeletal disorders is systematically higher in women than in men. Clin J Pain 22(8):717–724PubMedCrossRefGoogle Scholar
  29. 29.
    Burroughs K, Walker K (2012) “Hip fractures in adults,” UpToDate, no. Topic 226, Version 12.0Google Scholar
  30. 30.
    Milken Institute, “An unhealthy America: the economic burden of chronic disease.” Santa Monica, CA, Milken Institute 2012Google Scholar
  31. 31.
    Weiss CO (2011) Frailty and chronic diseases in older adults. Clin Geriatr Med 27(1):39–52PubMedCrossRefGoogle Scholar
  32. 32.
    Pang MY (2010) Whole body vibration therapy in fracture prevention among adults with chronic disease. World J Orthop 1(1):20–25PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Dennison E M, Compston J E, Flahive J, Siris E S, Gehlbach S H, Adachi J D, Boonen S, Chapurlat R, Díez-Pérez A, Anderson Jr F A, Hooven F H, Lacroix A Z, Lindsay R, Netelenbos J C, Pfeilschifter J, Rossini M, Roux C, Saag K G, Sambrook P, Silverman S, Watts N B, Greenspan S L , Premaor M, Cooper C (2012) “Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW)”. Bone: MarGoogle Scholar
  34. 34.
    Marzetti E, Leeuwenburgh C (2006) Skeletal muscle apoptosis, sarcopenia and frailty at old age. Exp Gerontol 41(12):1234–1238PubMedCrossRefGoogle Scholar
  35. 35.
    Woods JL, Iuliano-Burns S, King SJ, Strauss BJ, Walker KZ (2011) Poor physical function in elderly women in low-level aged care is related to muscle strength rather than to measures of sarcopenia. Clin Interv Aging 6:67–76PubMedCentralPubMedGoogle Scholar
  36. 36.
    Mahalakshmi VN, Ananthakrishnan N, Kate V, Sahai A, Trakroo M (2004) Handgrip strength and endurance as a predictor of postoperative morbidity in surgical patients: can it serve as a simple bedside test? Int Surg 89(2):115–121PubMedGoogle Scholar
  37. 37.
    Sultan P, Hamilton MA, Ackland GL (2012) Preoperative muscle weakness as defined by handgrip strength and postoperative outcomes: a systematic review. BMC Anesthesiol 12:1PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Chrischilles E, Shireman T, Wallace R (1994) Costs and health effects of osteoporotic fractures. Bone 15(4):377–386PubMedCrossRefGoogle Scholar
  39. 39.
    Tosteson AN, Rosenthal DI, Melton LJ 3rd, Weinstein MC (1990) Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 113(8):594–603PubMedCrossRefGoogle Scholar
  40. 40.
    U. S. C. O. of T (1993) Assessment, hip fracture outcomes in people age 50 and over: mortality, service use, expenditures, and long-term functional impairment. The OfficeGoogle Scholar
  41. 41.
    Cummings SR, Rubin SM, Black D (1990) “The future of hip fractures in the United States. Numbers, costs, and potential effects of postmenopausal estrogen,”. Clin Orthop Relat Res 252:163–166PubMedGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2013

Authors and Affiliations

  • Yang Zhao
    • 1
  • Shih-Yen Chen
    • 2
  • Yuan-Chi Lee
    • 2
  • Ning Wu
    • 2
  1. 1.Novartis Pharmaceuticals CorporationOne Health PlazaEast HanoverUSA
  2. 2.United BioSource CorporationLexingtonUSA

Personalised recommendations